Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MiMedx GroupMDXG +3.21%57 Equity-to-Asset is 0.77 as of Jun. 2026, which is 103% above its 10-year median of 0.38. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.51 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,415 Biotechnology companies, MiMedx Group ranks better than 61.13% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. MiMedx Group's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $216.0 Mil. MiMedx Group's Total Assets for the quarter that ended in Jun. 2026 was $281.0 Mil.
Therefore, MiMedx Group's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.77.
The historical rank and industry rank for MiMedx Group's Equity-to-Asset or its related term are showing as below:
MDXG'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.11 Med: 0.38 Max: 0.8
Current: 0.77
During the past 13 years, the highest Equity to Asset Ratio of MiMedx Group was 0.80. The lowest was -0.11. And the median was 0.38.
MDXG's Equity-to-Asset is ranked better than 61.13% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs MDXG: 0.77
MiMedx Group (NAS:MDXG) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
MiMedx Group Equity-to-Asset Related Terms
MiMedx Group Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for MiMedx Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDXG vs RGNX, ACHV, AGMB: Equity-to-Asset Comparison
For the Biotechnology subindustry, MiMedx Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where MiMedx Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
MiMedx Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group (MDXG) has a Equity-to-Asset of 0.77 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MiMedx Group and its competitors. This is 103% above median its historical median of 0.38. According to the industry distribution chart, MiMedx Group ranks #550 out of 1415 companies in the Biotechnology industry, placing it in the top 38.9%.
Is MiMedx Group's Equity-to-Asset too high?
MiMedx Group's current Equity-to-Asset of 0.77 is 103% above median its 10-year median of 0.38. The Biotechnology industry median Equity-to-Asset is 0.68. MiMedx Group's value of 0.77 is 13.2% above this industry median. Based on the distribution chart, MiMedx Group ranks #550 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Equity-to-Asset compare to RGNX and ACHV?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #550 out of 1415 companies for Equity-to-Asset. This puts MiMedx Group in the upper half of its industry. The industry median Equity-to-Asset is 0.68. MiMedx Group's value of 0.77 is 13.2% above this benchmark. While the company's 10-year median is 0.38 vs. the industry median of 0.68, MiMedx Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MiMedx Group's current Equity-to-Asset of 0.77 is 13.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MiMedx Group and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MiMedx Group's current Equity-to-Asset is 0.77, which is 103% above median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.51, compared to a current price of $4.35 — trading 33.2% below its estimated fair value. The current Equity-to-Asset is 0.77, which is 103% above median its 10-year median of 0.38 and 13.2% above the Biotechnology industry median of 0.68. MiMedx Group's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Equity-to-Asset is 0.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $4.35 is trading 33.2% below its estimated GF Value™ of $6.51.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
Equity-to-Asset: 0.77 (103% above median its 10-year median of 0.38)
GF Value™: $6.51 vs. price of $4.35 (33.2% below fair value)
Industry Position: 13.2% above the Biotechnology median (#550 of 1415)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score
Get the complete analysis for MDXG
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
